| __timestamp | Agios Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 7459000 |
| Thursday, January 1, 2015 | 141827000 | 11831000 |
| Friday, January 1, 2016 | 220163000 | 25705000 |
| Sunday, January 1, 2017 | 292681000 | 46181000 |
| Monday, January 1, 2018 | 341324000 | 59497000 |
| Tuesday, January 1, 2019 | 410894000 | 65003000 |
| Wednesday, January 1, 2020 | 367470000 | 74506000 |
| Friday, January 1, 2021 | 256973000 | 126006000 |
| Saturday, January 1, 2022 | 279910000 | 126215000 |
| Sunday, January 1, 2023 | 288903000 | 120161000 |
| Monday, January 1, 2024 | 301286000 |
Igniting the spark of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Agios Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments.
Agios Pharmaceuticals has consistently led the charge, with its R&D expenses peaking in 2019, reflecting a 310% increase from 2014. This surge underscores Agios's dedication to pioneering new therapies. Meanwhile, Protagonist Therapeutics has shown a remarkable growth trajectory, with its R&D spending increasing by over 1,500% from 2014 to 2023. This rapid rise highlights Protagonist's aggressive push into the biotech arena.
As we look to the future, these trends suggest a vibrant landscape for innovation, with both companies poised to make significant contributions to the field of biotechnology.
AbbVie Inc. or Protagonist Therapeutics, Inc.: Who Invests More in Innovation?
United Therapeutics Corporation vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Incyte Corporation vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Insmed Incorporated and Protagonist Therapeutics, Inc.
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Agios Pharmaceuticals, Inc.
R&D Spending Showdown: Madrigal Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Alkermes plc and Protagonist Therapeutics, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.
R&D Spending Showdown: MorphoSys AG vs Agios Pharmaceuticals, Inc.
R&D Insights: How Protagonist Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated Allocate Funds
Soleno Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Agios Pharmaceuticals, Inc. and Wave Life Sciences Ltd. Allocate Funds